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Abstract  The  aim  was  to  review  the  published  literature  on  corneal  collagen  cross-linking.  The
emphasis was  on  the  seminal  publications,  systemic  reviews,  meta-analyses  and  randomized
controlled  trials.  Where  such  an  evidence  did  not  exist,  selective  large  series  cohort  studies,
case controlled  studies  and  case  series  with  follow-up  preferably  greater  than  12  months  were
included.  Riboﬂavin/Ultraviolet  A  (UVA)  corneal  collagen  cross-linking  appears  to  be  the  ﬁrst
treatment  modality  to  halt  the  progression  of  keratoconus  and  other  corneal  ectatic  disorders
with improvement  in  visual,  keratometric  and  topographic  parameters  documented  by  most
investigators.  Its  precise  mechanism  of  action  at  a  molecular  level  is  as  yet  not  fully  determined.
Follow-up is  limited  to  4--6  years  at  present  but  suggests  continued  stability  and  improvement  in
corneal shape  with  time.  Most  published  data  are  with  epithelium-off  techniques.  Epithelium-
on studies  suggest  some  efﬁcacy  but  less  than  with  the  epithelium-off  procedures  and  long-
term data  are  not  currently  available.  The  use  of  Riboﬂavin/UVA  CXL  for  the  management
of infectious  and  non-infectious  keratitis  appears  very  promising.  Its  use  in  the  management
of bullous  keratopathy  is  equivocal.  Investigation  of  other  methodologies  for  CXL  are  under
investigation.
© 2013  Spanish  General  Council  of  Optometry.  Published  by  Elsevier  España,  S.L.  All  rights
reserved.
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Entrecruzamiento  del  colágeno  corneal:  Revisión
Resumen  El  objetivo  fue  revisar  la  literatura  publicada  sobre  el  tratamiento  de
entrecruzamiento  del  colágeno  corneal  (CXL),  principalmente  las  publicaciones  funda-
mentales, revisiones  sistémicas,  meta-análisis  y  ensayos  controlados  aleatorios.  Cuando
tales evidencias  no  existieron,  se  incluyeron  estudios  selectivos  de  grandes  series  de
poblaciones,  estudios  controlados  de  casos  y  series  de  casos,  con  un  seguimiento
preferiblemente  superior  a  doce  meses.  El  entrecruzamiento  del  colágeno  corneal  con
Riboﬂavina/Ultravioleta  A  (UVA)  parece  constituir  la  primera  modalidad  de  tratamiento
que detiene  la  progresión  del  queratocono  y  otros  trastornos  ectáticos  corneales,  con
mejora de  los  parámetros  visuales,  queratométricos  y  topográﬁcos,  según  lo  documen-
tado por  muchos  investigadores.  El  mecanismo  especíﬁco  de  acción  a  nivel  molecular  no
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ha  sido  totalmente  determinado  aún.  El  seguimiento  se  limita  a  4--6  an˜os  actualmente,  aunque
sugiere la  estabilidad  y  mejora  continuas  de  la  forma  corneal  con  el  tiempo.  Muchos  datos  pub-
licados se  reﬁeren  a  las  técnicas  sin  desbridamiento  epitelial.  Los  estudios  sin  desbridamiento
epitelial  sugieren  cierta  eﬁcacia,  aunque  menor  a  la  de  las  intervenciones  con  desbridamiento
epitelial,  no  disponiéndose  actualmente  de  información  a  largo  plazo.  El  uso  del  CXL  con
Riboﬂavina/UVA  para  el  tratamiento  de  la  queratitis  infecciosa  y  no  infecciosa  parece  muy
prometedor.  Su  uso  en  el  tratamiento  de  la  queratopatía  bullosa  es  equívoco.  Se  está  llevando
a cabo  una  investigación  de  otras  metodologías  de  CXL.
© 2013  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  España,  S.L.  Todos  los
derechos reservados.
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orneal  ectatic  disorders
eratoconus  is  a  degenerative  disorder  distinguished  by
ara-central  corneal  thinning  and  secondary  ectasia,  result-
ng  in  irregular  astigmatism  with  impaired  vision,  ghosting
nd  polyopia.1--3 It  is  typically  bilateral  but  often  asym-
etrical.  Onset  typically  is  at  puberty  with  progression  of
isease  for  10--20  years  when  it  tends  to  stabilize.  It  is
he  commonest  corneal  dystrophy,  affecting  about  1  in  1750
ndividuals.  It  occurs  in  all  racial  groups  and  equally  affects
ales  and  females.1--3 Studies  of  quality  of  life  analysis
eport  that  that  its  magnitude  of  public  health  impact  is
isproportionate  to  its  prevalence.4 Scores  of  life  impair-
ent  are  equivalent  to  grade  3--4  age  related  macular
egeneration.4
Its  aetiology  is  not  understood  and  includes  genetic,
iochemical,  and  physical  factors,  with  no  sole  proposed
heory  elucidating  its  range  of  clinical  presentations  and
t  is  probable  that  keratoconus  is  the  eventual  manifesta-
ion  for  several  different  conditions.  It  usually  appears  as  an
solated  condition,  but  has  been  associated  with  a  number
f  ocular  and  systemic  disorders,  including,  vernal  disease,
etinitis  pigmentosa,  blue  sclera,  atopy,  magnesium  deﬁ-
iency,  Down’s  syndrome,  Turner  syndrome  and  connective
issue  disorders  such  as  Marfans  syndrome,  Ehlers--Danlos
yndrome,  osteogenesis  imperfect  and  pseuodoxanthoma
lasticum.1,2 It  has  been  related  to  repeated  surface  ocu-
ar  trauma  associated  with  hard  contact  lens  wear,  allergic
ye  disease  and  eye  rubbing.1,2 Genetic  factors  are  impor-
ant  up  to  10%  having  a  family  history  of  the  condition.5
n  increased  activity  of  proteinase  enzymes  and  reduced
ctivity  of  proteinase  inhibitors  have  been  identiﬁed  in
eratoconic  corneas,6 with  the  increased  stromal  protein
igestion  resulting  in  reduced  biomechanical  stability  and
orneal  thinning.7 There  appears  to  be  an  inverse  relation-
hip  between  severity  of  the  condition  and  diabetes.8
Pellucid  marginal  corneal  degeneration  (PMD)  is  less
ommon  than  keratoconus.  It  usually  affects  the  inferior
eripheral,  rather  than  para-central,  cornea  in  about  85%  of
ases  and  the  superior  peripheral  cornea  in  15%.  It  occurs  in crescentic  fashion  typically  between  the  5  and  7  o’clock
ositions.9,10 It  is  more  common  in  males,  with  a  male  to
emale  ratio  of  approximately  3:1.10 Its  age  of  onset  is  usu-
c
t
c
klly  later  than  keratoconus,  presenting  between  the  2nd
nd  5th  decades.  It  is  typically  bilateral  and  affects  all
thnicities.9,10 The  incidence  and  aetiology  of  PMD  remain
nknown.  It  often  presents  with  progressive  with  severe
gainst  the  rule  astigmatism  typically  with  good  spectacle
orrected  acuity  until  the  advanced  stages  of  the  disease.
ydrops  and  even  spontaneous  perforation  can  occur.9,10
opography  typically  shows  a  ‘‘lobster-claw  pattern’’  but
his  is  not  pathognomonic  and  may  also  occur  in  keratoconus
nd  there  is  overlap  between  the  two  conditions,  as  well  as
ith  keratoglobus.10,11
Kerectasia  after  refractive  surgery  is  a  rare  but  often
isually  devastating  complication.  It  was  ﬁrst  described
fter  Laser  in  situ  keratomileusis  (LASIK)  by  Seiler  in  1998.12
t  reported  incidence  ranges  from  0.04  to  0.6%  of  post-
ASIK  cases,13,14 with  one  survey  reporting  that  over  50%
f  responding  refractive  surgeons  had  documented  at  least
ne  of  their  patients  with  such  problems.15 Its  onset  is  vari-
ble,  ranging  from  1  to  45  months  after  surgery  with  50%
f  cases  occurring  within  12  months.13 It  is  often  visually
evastating  with  one  study  in  the  early  2000s  reporting  that
5%  of  cases  eventually  required  corneal  transplantation.16
s  well  as  following  LASIK  it  has  also  been  reported  after
hotorefractive  keratectomy  (PRK)13,17,19 and  other  forms  of
eratorefractive  surgery  such  as  radial  keratotomy.18 Care-
ul  pre-operative  screening  is  essential  to  reduce  occurrence
nd  identiﬁed  risk  factors  include  pre-existing  keratoconus
nd  PMD,  including  forme  fruste  cases,  thin  corneas,  high
yopic  corrections,  residual  stromal  bed  less  than  250  m
nd  young  age,13,16,17,19 although  ectasia  can  occasion-
lly  occur  in  patients  without  currently  identiﬁable  risk
actors.16,19
Management  of  keratoconus,  PMD  and  post-surgery  ecta-
ia  depends  on  their  severity  and  the  extent  of  irregular
stigmatism.  Mild  cases  are  correctable  with  spectacles
nd  soft  toric  contact  lenses.  However,  with  progressive
isease,  the  cornea  becomes  more  irregular  and  rigid  gas
ermeable  lenses  are  required.20 In  15--20%  of  keratoconic
atients,  surgery,  typically  keratoplasty,  becomes  necessary,
s  a result  of  contact  lens  intolerance,  corneal  scarring  and
hinning.21 None  of  these  interventions,  while  often  success-
ul  in  terms  of  visual  rehabilitation,  treat  the  underlying
auses  of  kerectasia  and  its  progression.  It  is  only  with
he  advent  of  corneal  collagen  cross-linking  (CXL)  that  we
an  hope  to  slow,  stop  or  even  to  a  limited  extent  reverse
eratoconus.22--24
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Background
CXL  processes  occur  physiologically  with  age  via  nat-
ural  enzymatic  pathways  such  as  transglutaminase  and
lysyl  oxidase.  Photochemical  CXL  with  Riboﬂavin  (vitamin
B2)/Ultraviolet  A  (UVA)  (370  nm)  was  developed  at  the  Uni-
versity  of  Dresden  by  Spoerl  and  Seiler.22--25 They  postulated
that  the  procedure  induces  physical  cross-linking  of  colla-
gen  by  Riboﬂavin  absorbing  UVA  to  act  as  a  photo  sensitizer
to  produce  free  radicals  (oxygen  singlets)  that  activate
the  natural  lysyl  oxidase  pathway.25 By  absorbing  UVA,  the
Riboﬂavin  also  prevents  damage  to  deeper  ocular  struc-
tures,  including  as  the  endothelium,  lens  and  retina.25 A
more  recent  paper  has  corroborated  the  importance  of  sin-
glet  oxygen  production,  created  by  the  interaction  of  UVA
and  Riboﬂavin,  in  the  CXL  process.26 The  singlets  are,  how-
ever,  thought  not  to  instigate  cross-linking  by  lysyl  oxidase
but  possibly  by  three  other  mechanisms:  imidazolone  pro-
duction,  which  can  attach  to  molecules,  such  as  histidine,
to  form  new  covalent  bonds;  the  triggering  of  endogenous
populations  of  carbonyl  groups  in  the  ECM  (allysine,  hydrox-
yallysine)  to  form  cross-links  there,  and/or  the  degradation
of  the  Riboﬂavin  molecule  itself,  releasing  2,3-butanedione,
which  can  react  with  the  endogenous  carbonyl  groups  of
the  stromal  proteins.26 The  precise  location  of  the  cross-
links  at  a  molecular  level  is  as  yet  undetermined.  Certainly,
cross-links  cannot  form  between  the  collagen  ﬁbrils  as  the
distance  is  too  far  for  the  formation  of  intra-molecular
bonds.  Hayes  et  al.  in  a  series  of  ex  vivo  ungulate  and  rabbit
eyes  investigated  corneal  stromal  ultrastructure  using  X-ray
scattering,  hydrodynamic  behaviour  and  enzyme  digestion
and  determined  that  it  was  likely  that  the  cross  links
formed  during  Riboﬂavin/UVA  therapy  were  occurring  pre-
dominantly  at  the  collagen  ﬁbril  surface,  rather  than  within
the  ﬁbrils  themselves,  and  in  the  protein  network  surround-
ing  the  collagen.27
Laboratory  studies:  biomechanical  and  biochemical
considerations
There  is  no  deﬁnite  evidence  for  CXL  producing  corneal  col-
lagen  and  protoeglycan  cross-links,  as  these  molecular  bonds
cannot  be  seen  microscopically.  Ex  vivo,  laboratory  studies,
however,  have  reported  changes  in  physico-chemical  proper-
ties  of  the  stroma  following  CXL.  Stress-strain  measurements
of  corneal  stromal  tissue  are  signiﬁcantly  increased,24,28
both  immediately  as  well  as  several  months  following  the
procedure.29 These  changes  have  been  shown  to  principally
occur  in  the  anterior  200  m  of  the  stroma  where  the  most
of  the  UVA  absorption  takes  place.30 A  higher  shrinkage
temperature  has  been  demonstrated  in  corneal  tissue  fol-
lowing  CXL,  with  a  greater  effect  being  reported  in  the
anterior  stroma.31 Increased  resistance  of  stromal  tissue  to
enzymatic  digestion  has  been  conﬁrmed  after  CXL,  with  a
dose  response  in  relation  to  the  UVA  intensity.32 In  addition,
an  increased  resistance  to  matrix  metalloprotienase  (MMP),
in  particular  sub-types  MMP-1,  2,  9,  and  13,  degradation
of  collagen  and  small  leucine-rich  proteoglycans  following
Riboﬂavin/UVA  CXL  has  been  found.33 The  protective  effect
of  CXL  on  collagen  and  proteoglycans  from  MMP  cleavage  is
likely  to  be  important  in  the  mechanism  of  preventing  the
t
p
t
a115
rogression  of  keratoconus  and  other  corneal  ectatic  disor-
ers,  where  an  increased  activity  in  collagenases  has  been
stablished.19 Other  biophysical  and  biomechanical  alter-
tions  include,  an  increase  in  collagen  ﬁbre  diameter  in
abbit  corneas,34 and  a  signiﬁcant  reduction  in  the  hydration
ehaviour  of  the  stroma,  both  of  which  are  greater  in  the
nterior  compared  to  the  posterior  stroma.35 Recently,  how-
ver,  other  investigators  have  suggested  that  such  changes
re  probably  short-term  alterations,  due  to  a  consequence
f  the  effects  of  the  osmolarity  of  the  Riboﬂavin  solutions
sed  rather  than  actual  effects  of  cross-linking  and  not  likely
o  be  long-term  changes.27,36 In  addition  to  the  above,  there
re  alterations  in  the  electrophoretic  pattern  of  corneal  col-
agen  type  I  after  CXL,  with  the  occurrence  of  an  extra
ntense  polymer  band,  with  a  molecular  size  of  approxi-
ately  1000  kDa,  resistant  to  mercaptoethanol,  heat,  and
epsin.37
aboratory  studies:  safety
VA  is  cytotoxic.  It  can  cause  keratocyte  apoptosis  and  most
igniﬁcantly  endothelial  cell  damage  and  death  and  perma-
ent  lens  and  retinal  injury.38--41 Studies  with  cell  cultures
ave  found  an  increased  cytotoxic  irradiance  level  with
VA  irradiation  combined  with  photosensitizing  Riboﬂavin
or  keratocytes,  which  in  the  clinical  setting  would  occur
n  human  corneas  to  a  depth  of  300  m.38 With  regard  to
ndothelial  damage,  cell  culture  studies  have  demonstrated
 cytotoxic  threshold  level  above  0.35  mW/cm2 UVA  expo-
ure  for  30  min.39 This  should  not  be  reached  in  the  clinical
etting  with  corneal  thickness  greater  than  400  m.39 In  vivo
tudies  have  conﬁrmed  these  results  and  have  demonstrated
hat  with  UVA  exposure  of  3  mW/cm2 for  30  min,  that  over
5--90%  of  UVA  radiation  is  absorbed  by  the  Riboﬂavin  in  the
nterior  400  m  of  the  stroma,  so  that  the  irradiance  at  the
evel  of  the  endothelium  is  less  than  0.18  mW/cm2,  i.e.  50%
ess  than  the  cytotoxic  level.40,41 This  is  situation  is  the  same
or  other  internal  structures,  such  as  the  lens  and  retina,
here  the  level  of  UVA  radiation  reaching  these  structures
s  less  than  3%  of  the  cytotoxic  threshold.41
linical  studies
he  ﬁrst  reported  clinical  application  of  CXL  was  not  for
eratoconus,  but  to  treat  corneal  ulceration.  It  was  shown
o  effectively  halt  corneal  melting  in  3  out  of  4 treated
yes.42 The  ﬁrst  published  study  of  its  use  in  keratoconus
as  done  in  2003.25 Wollensak,  Spoerl  and  Seiler  reported  a
eries  of  23  keratoconic  eyes,  in  which  there  was  stabiliza-
ion  of  ectasia  following  CXL,  with  up  to  ﬁve  years  follow-up
n  a  few  eyes.  In  70%  of  cases  an  improvement  in  ectasia  was
een,  with  a  decrease  of  maximal  keratometry  by  2  diopters
D)  and  the  refractive  error  by  1  D.  There  was  no  long-
erm  loss  of  transparency  of  the  cornea  or  lens  in  any  eye
nd  endothelial  counts  were  unaltered  post-operatively.25
ultiple  subsequent  prospective,  non-randomized  studies
ith  up  to  24  months  follow-up  from  other  research  groups
hroughout  the  world,43--54 including  case  series  of  paediatric
atients55,56 and  advanced  keratoconus,57 have  conﬁrmed
hese  encouraging  initial  results.  Typically  they  report  ker-
toconic  stabilization  in  the  vast  majority  of  treated  eyes
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ith  few  complications  (see  complications  section  below)
nd  signiﬁcant  post-operative  improvements  in  visual  per-
ormance,  reductions  in  keratometry/corneal  power  and
eductions  in  higher  order  aberrations.43--57 Similar  promising
eports  of  case  series  of  CXL  in  post-laser  refractive  surgery
ctasia  have  been  published  with  stability  and  improved
ision  being  attained  with  over  2  years  follow-up,58--60 with
uccessful  outcomes  also  reported  in  individual  case  reports
f  CXL  for  PMD.61,62
While  the  outcomes  of  these  prospective  studies  have
een  very  encouraging,  there  is  a  scarcity  of  random-
zed,  prospective  clinical  studies  within  the  literature.  The
ew  published  studies,  however,  do  support  the  efﬁcacy
f  the  technique.  Wittig-Silva  published  interim  results  of
 randomized,  bilateral  study  in  33  eyes  at  6  months,
hich  showed  an  average  reduction  in  corneal  power  of
.9  diopters  (D)  in  treated  eyes  and  an  increase  of  0.6  D
n  untreated  eyes.63 To  date  the  completed  study  remains
npublished.  O’Brart  et  al.  in  a  completed,  randomized,
rospective,  bilateral  study  in  22  patients  with  documented
eratoconic  progression,  reported  stabilization  in  all  treated
yes  with  statistically  signiﬁcant  improvements  in  BSCVA,
orneal  power  measurements  and  higher  order  aberrations
nd  progression  in  14%  of  untreated  eyes  over  the  18  month
ollow-up  period.64 Further  randomized  prospective  studies,
ncluding  that  conducted  by  the  Food  and  Drug  Administra-
ion  should  hopefully  be  published  in  the  near  future.
XL  in  combination  with  other  treatment
odalities
s  an  isolated  treatment,  CXL  has  been  used  in  combi-
ation  with  other  treatment  modalities  to  optimize  visual
utcomes  in  keratoconic  and  post-laser  ectasia.  Combined
XL  and  limited  topography-guided  PRK  in  selected  eyes
ith  moderate  ectasia  and  adequate  corneal  thicknesses  has
een  shown  to  be  effective  with  marked  improvements  in
isual,  refractive  and  topographic  parameters  and  stabiliza-
ion  of  the  ectatic  process  in  the  vast  majority  eyes.65--69
uch  treatments  have  been  shown  to  be  associated  with  sig-
iﬁcant  improvements  in  quality  of  life  scores.70 Follow-up
n  these  studies,  however,  is  limited  to  only  1--3  years  so
hat  long-term  biomechanical  stability  has  not  been  fully
lucidated.  In  addition  signiﬁcant  corneal  haze/scarring  has
een  reported.71 CXL  has  also  been  used  after  intra-corneal
ing  segment  (ICRS)  insertion  and  even  in  a  three  step  pro-
edure  with  both  PRK  and  ICRS  insertion.72 Some  studies
ave  suggested  that  CXL  may  have  an  additive  effect,73,74
lthough  this  has  not  been  demonstrated  in  all  studies.75
XL  has  also  been  used  in  conjunction  with  keratorefrac-
ive  procedures  such  as  PRK  and  LASIK  in  an  attempt  to
mprove  long-term  stability  and  reduce  the  possible  occur-
ence  of  post-surgery  ectasia.76,77 As  yet,  such  studies  are
ery  limited  in  terms  of  numbers  treated,  efﬁcacy  and  long-
erm  follow-up,  although  a  single  contralateral  eye  study  in
f  CXL  after  hyperopic  LASIK  demonstrated  less  regression
f  correction  over  the  limited  follow-up  period.78ong-term  follow-up
hile  clinical  studies  certainly  support  the  mid-term  efﬁ-
acy  of  CXL,  there  is  a  paucity  of  long-term  data.
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eratoconus  typically  progresses  at  a  variable  rate,  for  up  to
wo  decades  following  presentation  and  then  tends  to  sta-
ilize,  presumably  as  a  result  of  physiological  age-related
ross-linking.1--3 The  turnover  rate  of  corneal  collagen  and
he  extracellular  matrix  (ECM)  is  unknown.  Taking  these  fac-
ors  into  consideration,  the  length  of  efﬁcacy  of  CXL  and  the
eed  to  repeat  the  procedure  is  uncertain.  Table  1  docu-
ents  the  outcomes  of  those  prospective  case  series  in  the
ublished  literature  with  follow-up  of  24  months  or  more.
nly  a  few  groups  have  actually  presented  data  with  over
--4  year  follow-up.  Raiskup-Wolf  et  al.  reported  33  eyes
ith  over  3  year  follow-up  and  found  stabilization  of  ker-
toconus  with  reduction  of  keratometry  and  improvements
n  vision  with  time.79 Caporossi  et  al.  detected  keratoconus
tability  in  44  eyes  after  48  months,  with  a reduction  in  ker-
tometry  and  coma  and  improvements  in  vision.80 O’Brart
t  al.  in  a  series  of  29  eyes  of  29  patients  with  4--6  years
ollow-up  found  ectatic  stabilization  in  all  eyes,  with  signiﬁ-
ant  improvements  in  refraction,  visual  acuity,  keratometry
nd  corneal  wave-front  measurements.81 In  addition  and
imilar  to  the  ﬁndings  of  Raiskup-Wolf  et  al.,79 they  docu-
ented  continued  improvements  in  keratometry  and  higher
rder  aberrations  with  follow-up  from  1  to  4--6  years  and
imilar  to  Caporossi  et  al.,80 25%  of  their  initially  untreated
ellow  eyes  demonstrated  evidence  of  progression.81 Fig.  1
hows  the  difference  map  of  a typical  patient  in  their  series,
 years  after  CXL  with  ﬂattening  of  the  apex  of  the  cone
esulting  in  an  improvement  in  corneal  shape,  reduction  in
igher  order  aberrations  and  enhancement  in  visual  perfor-
ance.  Similarly,  Hashemi  et  al.  demonstrated  stabilization
n  40  eyes  of  32  patients  with  progressive  keratoconus  with
ontinued  improvement  in  elevation  measurements  over  5
ears  of  follow-up82 and  Richoz  et  al.  reported  stabiliza-
ion  of  ectasia  after  LASIK  and  PRK  with  a  follow-up  of  over
 years  in  some  eyes  in  their  case  series.83 Such  ﬁndings
urther  support  the  efﬁcacy  of  CXL  up  to  4--6  years,  with
ocumented  progression  in  fellow  untreated  eyes  indicating
hat  improvements  in  measured  parameters  in  treated  eyes
ith  time  are  not  due  to  physiological  age-related  cross-
inking  changes.  Further  follow-up  will  determine  long-term
fﬁcacy  and  the  need  if  any  to  repeat  the  procedure  and  will
lucidate  how  long  and  to  what  degree  eyes  might  continue
ith  improvement  in  visual  and  topographic  parameters.
he  recurrence  of  keratoconus  following  keratoplasty,  which
ypically,  albeit  rarely,  occurs  10--20  following  surgery,84 sug-
ests  that  turnover  of  corneal  collagen  and  ECM  may  be
easured  in  decades  and  that  CXL  might  be  effective  for
t  least  this  length  of  time  if  not  longer  given  physiological
ross-linking  changes  with  age.
tandard  ‘‘epithelium-off’’  CXL  procedure
rior  to  CXL,  it  is  necessary  to  obtain  documented  evi-
ence  of  progression  of  the  condition.  To  reduce  the
isk  of  endothelial  damage  it  must  be  ensured  pre-
peratively  that  central  corneal  thickness  is  greater  than
00  m.25--27 Following  fully  informed  consent,  CXL  is
ypically  performed  under  topical  anaesthesia.  In  the
tandard  epithelium-off  technique  the  central  8--9  mm  of
he  corneal  epithelium  is  de-brided  to  enable  adequate
tromal  Riboﬂavin  absorption.25,43--64 Following  epithelial
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Table  1  Visual,  refractive  and  keratometric  changes  after  epithelium  off  Riboﬂavin  UVA  CXL  in  prospective  case  series  in  which
all eyes  have  a  reported  follow-up  of  24  months  or  more.
Lead  author  Year  Number
(eyes)
Follow-up
(months)
UDVA
change
(LogMar)
CDVA
change
(LogMar)
MSE  change
(D)
K  Max
change  (D)
Pachymetry
change
(m)
Failure  (%)
Raiskup  2008  33  >36  −0.15  −2.57  6
Caporossi A  2010  44  48  −0.37  −0.14  +2.15  −2.26  +0.6  0
Kampik D  2011  46  24  −0.05  −1.23  −21.6
Vinciguerra A  2012  40  24  −0.21  −0.19  +1.57  −1.27  +14.0
Goldich Y 2012  14  24  −0.08  −2.40  0
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de-bridement,  Riboﬂavin  0.1%,  suspended  in  a  dextran  T500
20%  solution,  is  applied  every  3--5  min  for  at  least  20  min
to  allow  sufﬁcient  stromal  uptake  prior  to  UVA  exposure.25
Intra-operative  pachymetry  is  advocated  by  many  surgeons
to  monitor  corneal  thickness  prior  to  UVA  exposure  and
administer  hypotonic  Riboﬂavin  drops  if  it  thins  excessively
during  Riboﬂavin  administration.  The  central  8--9  mm  of  the
cornea  is  then  irradiated  with  UVA,  at  3  mW/cm2 for  30  min.
During  this  time,  Riboﬂavin  drops  are  reapplied  to  the
stromal  surface  every  3--5  min  during  the  30-min  irradiation
period.  Following  treatment,  topical  antibiotics  and  corti-
costeroids  are  prescribed  until  corneal  re-epithelialisation.
Systemic  analgesic  and  bandage  soft  contact  lenses  can  be
used  for  pain  management.  Topical  anaesthetics  in  limited
dosage,  no  more  than  2  h  and  only  for  48  h  may  also  be  of
beneﬁt.85 Signiﬁcant  ocular  pain  is  typically  experienced
for  the  ﬁrst  24--48  h  following  surgery  and  vision  is  blurred
for  1--2  weeks.  Rigid  contact  lens  wear  can  be  resumed
once  the  epithelium  has  fully  healed,  typically  at  about
2--3  weeks.  Confocal  microscopy  has  identiﬁed  oedema,
superﬁcial  nerve  loss,  rarefaction  of  keratocytes  in  the
anterior  and  mid-stroma  and  isolated  endothelial  damage
in  the  immediate  post-operative  period.86--88 There  is  ker-
atocyte  re-population  during  the  ﬁrst  three  months,  which
d
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Figure  1  Difference  topographic  map  of  an  eye  with  keratoconus  
ﬂattening of  the  apex  of  the  cone  (green  colour)  with  some  slight  stee
Such changes  are  associated  in  an  improvement  in  corneal  higher  o
enhancements  in  visual  performance.+0.8  −1.06  +2.0  0
s  usually  completed  in  six  months.  An  increased  density  of
he  extracellular  matrix  occurs  to  a  depth  of  300--350  m.
his  forms  the  ‘‘demarcation  line’’  which  can  be  seen
n  slit  lamp  examination.89 Regeneration  of  nerve  ﬁbres,
ith  restoration  of  the  sub-epithelial  plexus  occurs  within
2  months  with  return  of  full  corneal  sensitivity.  These
onfocal  studies  have  conﬁrmed  the  lack  of  endothelial
amage,  with  no  alterations  of  cell  density  changes  or
exagonality.86--88 In  vivo  confocal  microscopic  changes
fter  CXL  have  been  conﬁrmed  by  histological  examination
f  corneal  buttons  after  keratoplasty.90--92 Such  studies
orroborate  keratocyte  loss  and  damage,  which  can  be
rolonged,90 with  an  increase  in  collagen  ﬁbril  diameter.90--92
pithelium  on  versus  epithelium  off  techniques
iboﬂavin  is  a  hydrophilic  molecule  which  cannot  easily
ass  the  tight  junctions  of  the  intact  epithelial  barrier.
poerl  conﬁrmed  the  need  for  complete  central  epithelial
ebridement  to  allow  sufﬁcient  stromal  uptake  of  Riboﬂavin
nd  reported  no  changes  in  the  biomechanical  proper-
ies  of  corneal  tissue  where  the  CXL  was  performed  with
he  epithelium  intact.23 On  the  basis  of  his  study,  the
4  years  after  epithelium  off  CXL  showing  the  typical  picture  of
pening  of  the  adjacent  superior  hemi-meridian  (orange  colour).
rder  aberrations,  especially  vertical  coma,  and  accompanying
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pithelium  was  removed  prior  to  Riboﬂavin  administration
n  the  ﬁrst  clinical  studies.25,43--64,79--83 In  spite  of  these  ﬁnd-
ngs,  some  clinicians  have  elected  to  perform  CXL  with
he  epithelium  intact74 or  partially  disrupted93 or  with
he  use  of  femtosecond-created  intra-stromal  pockets,94
n  an  attempt  to  reduce  post-operative  discomfort  and
id  visual  recovery.  The  use  of  repeated  applications  of
etracaine  1%  to  try  to  loosen  epithelial  tight  junctions
as  been  advocated.74 Others  investigators  have  utilized
imited  full-thickness  epithelial  debridement  in  a  grid
attern,  with  remaining  islands  of  intact  epithelium  to
id  post-operative  epithelial  healing.93 Laboratory  stud-
es,  employing  spectrophotometry  to  indirectly  measure
tromal  Riboﬂavin  absorption  have  shown  the  need  with
tandard  Riboﬂavin  solutions  to  completely  remove  the
entral  epithelium.95,96 Superﬁcial  epithelial  trauma,  pre-
perative,  multiple  administration  of  topical  tetracaine  1%,
pplication  of  20%  Alcohol  solution,  grid  pattern  epithelial
emoval  were  all  found  to  be  insufﬁcient  to  attain  adequate
omogeneous  Riboﬂavin  stromal  absorption.95,96 In  recent
ears,  novel  formulations  of  Riboﬂavin  have  been  devel-
ped  to  facilitate  trans-epithelial  absorption.  Laboratory
tudies  with  Riboﬂavin  preparations  in  which  trometamol
Tris--(hydroxymethyl)aminometane)  and  Sodium  Ethylene-
iaminetetraacetic  acid  (EDTA)  have  been  added  (Ricrolin
E®,  Sooft  Italia  S.p.A.)  have  been  shown  to  facilitate
tromal  absorption  especially  with  superﬁcial/grid  pattern
pithelial  trauma.97 Similarly,  preparations  without  dex-
ran  but  with  sodium  chloride  0.44%  and  benzalkonium
hloride  0.02%  and  0.04%  have  been  shown  to  facilitate
rans-epithelial  Riboﬂavin  stromal  absorption.98,99 Clini-
al  studies  with  such  novel  formulations  have  shown
ncouraging  results,  although  they  have  been  somewhat
quivocal  with  some  studies  suggesting  similar  efﬁcacy
o  standard  epithelium-off  techniques,100,101 and  others
ith  less  pronounced  effects.102--104 At  present  all  long-
erm  data  over  3  years  and  most  published  clinical
tudies  have  been  performed  with  ‘‘epithelium-off’’  pro-
edures  and  further  clinical  studies  with  longer  follow-up
nd  especially  randomized,  controlled  trials  are  required
o  ascertain  the  efﬁcacy  of  ‘‘epithelium-on’’  CXL  com-
ared  to  the  current  gold  standard  of  ‘‘epithelium-off’’
XL.
In  addition  to  the  novel  formulations  discussed  above,
n  vitro  studies  have  demonstrated  enhanced  trans-
pithelial  Riboﬂavin  absorption  using  iontophoretic  delivery
Vinciguerra  P.  et  al.  2012:  ARVO  E-Abstract  1518),  (Ziebarth
.N.  et  al.  2012:  ARVO  E-Abstract  2544).  Riboﬂavin  is  an
ffective  molecule  for  iontophoretic  transfer  as  it  is  small,
egatively  charged  at  physiological  pH  and  is  easily  soluble
n  water.  Clinical  studies  are  being  undertaken  with  a
ecently  published  study  of  22  eyes  with  mild  progressive
eratoconus  which  underwent  trans-epithelial  CXL  with  ion-
ophoresis  for  10  min  demonstrating  a  signiﬁcant  reduction
n  keratometry  and  corneal  astigmatism  post-operatively
ith  an  improvement  in  uncorrected  acuity.107 As  well  as
ontophoresis,  other  methodologies  currently  under  pre-
linical  investigation  to  facilitate  trans-epithelial  Riboﬂavin
tromal  absorption  include  the  use  of  ultrasound,108
ano-emulsion  systems109 and  other  epithelial  permeation
nhancers  such  as  d-alpha-tocopheryl  poly(ethylene  glycol)
000  succinate  (Vitamin  E-TPGS).110
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apid  (accelerated)  CXL  techniques
urrent  treatment  protocols  utilize  UVA  energies  of
 mW/cm2 and  require  30  min  of  UVA  exposure  to  achieve
he  desired  clinical  effect.25,43--64 It  has  been  theorized  that
y  increasing  the  UVA  ﬂuence  while  simultaneously  reducing
he  exposure  time  (the  Bunsen--Roscoe  law  of  reciprocity),
he  same  sub-threshold  cytotoxic  corneal  endothelial  UVA
osage  can  be  administered,  thereby  maintaining  efﬁcacy
nd  safety,  but  with  a reduced  treatment  time.  This  can
llow  improved  patient  comfort  and  convenience  as  well  as
hortened  keratocyte  exposure  time.  The  latter  may  perhaps
esult  in  less  keratocyte  damage  and  apoptosis.
Preclinical  ex  vivo  studies  have  been  encouraging,  with
imilar  biomechanical  changes  as  measured  by  scanning
coustic  microscopy  and  extensiometry,  seen  between  the
tandard  UVA  exposure  of  3  mW/cm2 for  30  min  compared
ith  higher  ﬂuencies  with  shorter  exposure  times,111,112
lbeit  with  a  sudden  decrease  in  efﬁcacy  with  very  high
ntensity  UV  light  greater  than  45  mW/cm2.113 This  decrease
n  efﬁcacy  with  higher  ﬂuencies  is  not  understood  but  might
e  related  to  oxygen  consumption  and  availability,  which
as  been  shown  to  limit  the  photochemical  cross-linking
rocess.26
Published  clinical  studies  at  present  are  few.  Cinar  et  al.
n  a  study  of  23  eyes  showed  that  accelerated  CXL  produced
 signiﬁcant  reduction  in  topographic  keratometry  values
nd  an  improvement  in  corrected  distance  acuity  with  a
imited  follow-up  of  6 months.114 Similarly,  Kanellopoulos
n  a  randomized,  prospective  study  using  a UVA  power  of
 mW/cm2 for  15  min  compared  to  3  mW/cm2 for  30  min  has
emonstrated  similar  clinical  results  as  the  standard  tech-
ique  in  terms  of  ectasia  stabilization  without  any  adverse
ffects  associated  with  the  higher  ﬂuence,  shorter  dura-
ion  treatments.115 Further  studies  using  higher  ﬂuencies
nd  shorter  exposure  times  are  either  underway  or  being
lanned  and  hopefully  future  CXL  treatment  times  should
e  considerably  shortened.
reatment  of  thin  corneas
ue  to  the  potential  of  endothelial  toxicity  and  cell  death,
XL  using  the  standard  protocol  is  contraindicated  for  indi-
iduals  with  corneas  thinner  than  400  m.  In  a  number  of
tudies,  hypo-osmolar  Riboﬂavin  solutions  have  been  used
o  swell  the  cornea  intra-operatively  to  over  400  m  and
nable  CXL  to  be  undertaken.  Raiskup  et  al.  in  a  series  of
2  eyes  with  corneas  thinner  than  400  m  showed  stabil-
ty  of  vision  and  keratometry  with  no  adverse  events  at  12
onths,116 while  Nassaralla  et  al.  in  18  eyes  demonstrated
welling  of  the  cornea  with  the  intra-operative  administra-
ion  of  hypo-osmolar  0.1%  Riboﬂavin  with  no  intraoperative,
arly  postoperative,  or  late  postoperative  complications.117
owever,  in  one  study  of  CXL  in  thin  corneas  endothe-
ial  counts  were  shown  to  be  slightly  reduced,  although
ision  and  keratometry  were  improved118 and  in  one  case
eport,  progression  continued  after  CXL  in  an  eye  with central  thickness  of  less  than  330  m.119 In  addition  to
he  use  of  hypo-osmolar  Riboﬂavin,  Spadea  and  Mencucci
emonstrated  efﬁcacy  with  no  endothelial  damage  with
rans-epithelial  CXL  in  corneas  at  thin  as  331--389  m.120
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More  clinical  series  and  follow-up  are  required  to  establish
if  these  procedures  in  thin  corneas  are  as  effective  and  safe
as  standard  CXL  in  corneas  with  thicknesses  greater  than
400  m.
New  methodologies
While  Riboﬂavin/UVA  CXL  has  been  shown  to  be  effec-
tive,  other  methodologies  which  are  potentially  more  rapid
and  less  invasive,  are  currently  under  investigation.  Rocha
et  al.  reported  a  ﬂash-linking  process  with  UVA  and  polyvinyl
pyrrolidone  with  may  have  the  potential  to  photo-chemically
cross-link  the  cornea  in  only  30  s.121 Paik  et  al.  have  inves-
tigated  the  topical  application  of  short-chain  aliphatic
beta-nitro  alcohols122 and  Cherfan  et  al.  demonstrated
an  almost  fourfold  increase  in  corneal  stiffness  with  no
reduction  in  keratocyte  viability  with  rose  bengal  0.1%
administration  and  green  light  application  and  a  less  than
5  min  total  treatment  time.123 Undoubtedly  other  method-
ologies  and  applications  will  become  available  over  the
several  next  years  due  to  the  vast  interest  in  this  area  of
research.
Adverse  effects  of  CXL
Clinical  studies  indicate  that  CXL  is  a  safe  procedure
with  few  sight-threatening  complications.  Adverse  events,
however,  can  occur  and  have  been  reported.  Reported
complications  include  corneal  haze  and  scarring,  reduced
uncorrected  and  BSCVA,  infectious  and  non-infectious  stro-
mal  melting  and  treatment  failure  with  progression  of
ectasia.
Haze
Mid-stromal  haze  occurs  in  the  majority  of  eyes,  typically
appearing  at  2--6  weeks  and  clearing  by  9--12  months.  It  is
the  result  of  an  increased  density  of  extracellular  matrix  and
arises  at  a  depth  of  300--350  m.  It  forms  the  demarcation
line  which  can  be  easily  seen  on  slit  lamp  examination.89
As  this  change  is  self-limiting,  topical  cortical  steroids  are
not  indicated.  Persistent  haze/scarring,  however,  can  occa-
sionally  occur.  Raiskup  reported  persistent  stromal  haze  at
12  months  in  8.6%  of  cases  in  a  series  of  163  eyes.124 Com-
pared  to  eyes  without  haze  in  this  series,  affected  eyes  had
a  higher  apex  power  (average  72  D),  higher  3.00  mm  ker-
atometry  (average  54.75  D)  and  thinner  central  pachymetry
(average  420  m).  On  the  basis  of  these  ﬁndings,  caution  and
careful  patient  counselling  before  CXL  is  advised  in  patients
with  advanced  keratoconus.125
Sterile  inﬁltrates
Sterile  inﬁltrates  may  occur  in  the  early  post-operative
period  and  usually  resolve  with  a  few  weeks  with  topical
corticosteroid  medication.  Koller  reported  sterile  inﬁltrates
in  8  eyes  (7.6%)  in  a  series  of  117  cases.  These  inﬁltrates
resolved  within  4  weeks  with  topical  dexamethasone  0.1%
treatment.125 More  rarely,  serious  cases  of  non-infectious
keratitis,  occurring  1--4  days  following  CXL,  with  loss  of
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SCVA  have  been  reported.  These  cases  have  been  typically
ssociated  with  a  possible  with  atopic  eye  disease.126 A  sin-
le  case  of  corneal  melting  associated  with  activation  of
erpes  simplex  keratitis  has  also  been  reported.127 It  is  pru-
ent  therefore  to  fully  control  atopic  eye  disease  prior  to
ross-linking  and  to  give  prophylactic  systemic  Acyclovir  in
atients  with  previous  Herpetic  Eye  disease.
nfectious  keratitis
nfectious  keratitis  post  CXL  has  been  reported.  This  is
o  be  expected  as  de-briding  the  corneal  epithelium  can
xpose  the  corneal  stroma  to  microbial  infection.  Cases
f  bacterial  infection  with  Staphylococcal  epidermidis,
scherichia  coli, Pseudomonas  aerunginosa  and  Coagulase
egative  Staphylococcus  as  well  as  Acanthamoeba  have  all
een  reported.128--130 A  number  of  these  cases  have  been
ssociated  with  post-operative  bandage  contact  lens  misuse.
t  is  important  to  inform  patients  not  to  replace,  remove  or
ry  to  clean  these  lenses  themselves.
ndothelial  failure
ndothelial  failure  has  been  reported  very  occasionally  after
XL  resulting  in  corneal  oedema  post-operatively.  Sharma
t  al.  in  a  retrospective  series  of  350  patients  treated
ith  a  standard  ‘‘epithelium-off’’  protocol  in  eyes  with
orneal  thicknesses  greater  than  400  m  after  epithelial
emoval,  reported  persistent  problems  in  5  patients  (1.4%),
 of  whom  (0.6%)  required  penetrating  keratoplasty.131
agga  et  al.  reported  a  single  case  with  keratouveitis
nd  endothelial  failure  that  required  keratoplasty.132 While
uch  complications  are  rare,  they  high-light  the  need  to
arn  patients  pre-operatively  of  severe  sight-threatening
omplications  and  the  very  occasional  need  for  keratoplasty
fter  CXL.  The  aetiology  of  such  problems  has  not  been
ully  elucidated  but  endothelial  damage  after  CXL  may  occur
ven  in  corneas  with  adequate  thickness  perhaps  due  to
evere  stromal  thinning  intra-operatively  due  to  the  use  of
yper-  and  iso-osmolar  Riboﬂavin  solutions  and/or  lack  of
omogenicity  with  hot  spots  in  the  UV  beams  associated  with
he  use  of  diodes  and  limited  focusing/alignment  systems.
rogression  of  ectasia
lthough  the  great  majority  of  eyes  are  stabilized  after
XL,  failure  of  treatment  with  progression  of  keratoecta-
ia  can  occur.  Raskup  in  a  series  of  241  eyes,  with  over
 month  follow-up,  reported  stabilization  in  98%  of  cases
ith  progression  identiﬁed  in  only  2  eyes.79 Koller  in  177
yes  described  progression  in  8  eyes  (7.6%).  They  identiﬁed
yes  with  advanced  keratoconus  with  maximum  keratome-
ry  values  greater  than  58  D  of  being  at  greatest  danger  of
rogression.125
ther  clinical  indications  for  CXL
ullous  keratopathy
s  some  initial  ex  vivo  laboratory  studies  reported  a  reduc-
ion  in  the  hydration  behaviour  of  the  corneal  stroma
fter  CXL,35 although  this  has  been  refuted  by  other
nvestigators,27,36 it  has  been  postulated  that  CXL  may
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e  efﬁcacious  in  the  management  of  bullous  keratopathy,
ither  to  delay  and/or  prevent  the  need  for  keratoplasty.  In
wo  studies  consisting  of  only  four  eyes,  corneal  pachymetry
as  found  to  be  reduced  at  6--8  months.133,134 A  more
ecent  study  reported  CXL  in  14  eyes  with  pain  secondary  to
seudophakic  bullous  keratopathy.135 Treatment  improved
orneal  transparency  and  reduced  corneal  thickness  and
ain  at  1  month  but  the  beneﬁcial  effects  reduced  with
ime  and  were  unchanged  from  pre-operative  levels  at
 month.135 Although  somewhat  equivocal,  further  longer
erm  studies  in  larger  patient  series  are  necessary  to  deter-
ine  the  efﬁcacy  of  CXL  for  this  indication.
icrobial  keratitis/corneal  ulceration
he  ﬁrst  published  clinical  application  of  CXL  was  actually
o  treat  corneal  ulceration  and  melting  and  demonstrated
essation  of  the  melting  process  in  3  out  of  4  eyes.42 The
bility  of  CXL  to  increase  the  resistance  of  corneal  tissue
o  enzymatic  digestion,  as  well  as  for  UVA  to  kill  microbes
ffers  great  promise  for  a  possible  role  in  the  treatment  of
icrobial  keratitis.  Within  the  literature  there  now  several
ase  series  of  CXL  in  eyes  with  microbial  keratitis,  including
ases  of  Acanthamoeba  and  fungal  infection,  unresponsive
o  anti-microbial  therapy.  In  the  majority  of  cases  progres-
ion  of  the  melting  process  was  halted  within  a  few  days
f  treatment  and  emergency  keratoplasty  avoided.136--138
his  potential  application  of  CXL  is  extremely  exciting  with
 recent  systemic-review  and  meta-analysis  by  Alio  et  al.
dentifying  12  published  articles  within  which  treatment  of
04  eyes  had  been  reported  and  from  which  pooled  analy-
is  suggested  that  CXL  had  a  favourable  effect  on  blocking
orneal  melting  in  85%  of  cases.139 CXL  may  offer  great
otential  in  the  treatment  of  microbial  keratitis  as  a  primary
s  well  as  secondary  therapy,  especially  given  the  increas-
ng  reports  of  anti-microbial  resistance  to  antibiotics  and
eports  of  its  usage  in  veterinary  practice  are  also  beginning
o  emerge.140,141
ummary
linical  studies  of  CXL  have  shown  great  promise  in  stabiliz-
ng  keratoconus  and  post-refractive  surgery  ectasia.  While
urther  randomized,  prospective  and  long-term  follow  up
tudies  are  necessary,  it  is  very  likely  that  in  the  future
orneal  ectasia  can  be  halted  at  an  early  stage  and  the  need
or  rigid  contact  lenses  and  keratoplasty  avoided.  Future
eﬁnement  in  techniques  will  allow  for  safer  and  more
apid  procedure  with  less  patient  discomfort.  Indications  for
ross-linking  both  in  Ophthalmology  and  other  branches  of
edicine  will  undoubtedly  expand,  with  the  potential  use
f  CXL  for  microbial  infections  begin  particularly  exciting.
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